Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL), a biopharmaceutical company, has announced its participation in three major upcoming investor conferences in September 2025. The company will participate in fireside chat sessions at the 2025 Wells Fargo Healthcare Conference on September 5, the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, and the H.C. Wainwright 27th Annual Global Investment Conference on September 10.

All presentations will be available via webcast on the company's investor relations website for 90 days following each conference.

News Market Reaction – AVDL

+0.96%

+0.96% Session close to close

In the Aug 29 session, AVDL gained 0.96%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:

• 2025 Wells Fargo Healthcare Conference: Fireside chat on Friday, September 5 at 11:00 a.m. ET.
• Morgan Stanley 23^rd Annual Global Healthcare Conference: Fireside chat on Tuesday, September 9 at 1:05 p.m. ET.
• H.C. Wainwright 27^th Annual Global Investment Conference: Fireside chat on Wednesday, September 10 at 9:30 a.m. ET.
  
  

A live webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following each conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Austin Murtagh
Precision AQ
Austin.murtagh@precisionaq.com
(212) 698-8696

Media Contact:
Alyssa Ramirez
Real Chemistry
aramirez@realchemistry.com

FAQ

When is Avadel Pharmaceuticals (AVDL) presenting at the Wells Fargo Healthcare Conference 2025?

Avadel Pharmaceuticals will present at the Wells Fargo Healthcare Conference on Friday, September 5, 2025 at 11:00 a.m. ET.

What time is Avadel's presentation at the Morgan Stanley Healthcare Conference 2025?

Avadel will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 9, 2025 at 1:05 p.m. ET.

How can investors access Avadel Pharmaceuticals' (AVDL) conference presentations?

Investors can access the live webcasts and archived recordings of the presentations on Avadel's Investor Relations website at investors.avadel.com. The recordings will be available for 90 days after each conference.

Which investor conferences is Avadel Pharmaceuticals (AVDL) attending in September 2025?

Avadel is attending three conferences: the Wells Fargo Healthcare Conference (Sept 5), Morgan Stanley Global Healthcare Conference (Sept 9), and H.C. Wainwright Global Investment Conference (Sept 10).